...
首页> 外文期刊>Medicine. >Coagulation Disorders and Bleedings in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis
【24h】

Coagulation Disorders and Bleedings in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis

机译:严重吞噬细胞性淋巴细胞增多症的重症患者的凝血障碍和出血

获取原文
获取原文并翻译 | 示例
           

摘要

Reactive hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition related to a cytokine storm leading to multiorgan dysfunction. A better understanding of coagulation disorders, frequently reported in HLH patients, may improve outcomes.Critically ill HLH patients managed in a multidisciplinary national reference center were retrospectively included. Relationships between coagulation disorders, severe bleedings, and outcomes were assessed.One hundred and seventeen patients fulfilled the HLH 2004 criteria. The most common HLH etiology was hematologic conditions (73%), followed by infectious diseases (20%), systemic rheumatic diseases (5%), and undetermined HLH etiology (3%). All patients exerted thrombocytopenia. Coagulation disorders were diagnosed in 79 (68%) patients (61 had hypofibrinogenemia<1.5g/L, 51 had prothrombin time [PT]<50%). The worst median value throughout ICU stay was 52% (38-65) for PT with a factor V level of 35% (27-43), 1.59 (1.30-2.09) for the activated partial thromboplastin time (APTT) ratio, and 2.33g/L (1.13-3.86) for the fibrinogen level. Disseminated intravascular coagulation (DIC) was found in 50% of patients. Coagulation disorders were more frequent in immunocompromised patients, those with histological/cytological feature of hemophagocytosis, those with the highest ferritin concentrations, and in patients with HLH not related to infection. These patients were more prone to receive mechanical ventilation, vasopressors, or renal replacement therapy. Twenty-six (22%) patients presented severe bleeding complications, including 5 patients dying from hemorrhagic shock. Strikingly, the only coagulation parameter significantly associated with severe bleeding was low fibrinogen with a cutoff value of 2g/L (P=0.03). Overall, 33 (28%) patients died in the ICU and hospital mortality was 44%. Coagulation disorders were associated with higher mortality, especially fibrinogen<2g/L (P=0.04) and PT value (P=0.03). The occurrence of bleeding complications was not associated with higher risk of hospital death. Risk factors associated with mortality by multivariate analysis were fibrinogen level<2g/L (OR 2.42 [1.08-5.41]), SOFA score>6 (OR 3.04 [1.32-6.98]), and age>46 years (OR 2.26 [1.02-5.04]).Up to two-third of critically ill HLH patients present with coagulation disorders. Hypofibrinogenemia or DIC was found in half of the patients and low PT in 40%. These patients require more life support and have a higher mortality rate. Fibrinogen <2g/L is associated with the occurrence of severe bleeding and mortality.
机译:反应性吞噬淋巴细胞组织细胞增生症(HLH)是与导致多器官功能障碍的细胞因子风暴有关的威胁生命的疾病。更好地了解HLH患者中经常报道的凝血功能障碍可能会改善预后。回顾性纳入在多学科国家参考中心治疗的重症HLH患者。评估了凝血功能障碍,严重出血和结局之间的关系.117名患者符合HLH 2004标准。 HLH最常见的病因是血液学状况(73%),其次是传染病(20%),系统性风湿病(5%)和HLH病因未定(3%)。所有患者均发生血小板减少症。在79(68%)位患者中诊断出凝血障碍(61位低纤维蛋白原血症<1.5g / L,51位凝血酶原时间[PT] <50%)。 PT在ICU停留期间最差的中间值是52%(38-65),因子V水平为35%(27-43),激活的部分凝血活酶时间(APTT)比率为1.59(1.30-2.09),以及2.33 g / L(1.13-3.86)(纤维蛋白原水平)。在50%的患者中发现了弥散性血管内凝血(DIC)。免疫功能低下的患者,具有吞噬作用的组织学/细胞学特征的患者,铁蛋白浓度最高的患者以及与感染无关的HLH患者的凝血障碍更为常见。这些患者更倾向于接受机械通气,升压药或肾脏替代治疗。二十六(22%)位患者出现严重的出血并发症,包括5位因失血性休克死亡的患者。引人注目的是,与严重出血有关的唯一凝血参数是低纤维蛋白原,其临界值为2g / L(P = 0.03)。总体而言,ICU中有33名患者(28%)死亡,医院死亡率为44%。凝血障碍与更高的死亡率相关,尤其是纤维蛋白原<2g / L(P = 0.04)和PT值(P = 0.03)。出血并发症的发生与更高的医院死亡风险无关。通过多因素分析与死亡率相关的危险因素是纤维蛋白原水平<2g / L(OR 2.42 [1.08-5.41]),SOFA评分> 6(OR 3.04 [1.32-6.98])和年龄> 46岁(OR 2.26 [1.02- 5.04]。多达三分之二的重症HLH患者出现凝血障碍。低纤维蛋白原血症或DIC在一半的患者中发现,低PT在40%。这些患者需要更多的生命支持,死亡率更高。纤维蛋白原<2g / L与严重出血和死亡的发生有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号